Bulk Inquiry
VX 770
- Ivacaftor - Kalydeco
Axon 2503
CAS:
873054-44-5
Purity:
99%
- Soluble in DMSO
- MF: C24H28N2O3
- MW: 392.49
Description
Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels.
More Information
| Parent CAS No. | 873054-44-5 |
|---|---|
| Chemical Name | N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide |
| SMILES | N1C2=C(C=CC=C2)C(=O)C(C(NC2=CC(O)=C(C(C)(C)C)C=C2C(C)(C)C)=O)=C1 |
| MFCD | MFCD17171361 |
| InChi | InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29) |
| InChiKey | PURKAOJPTOLRMP-UHFFFAOYSA-N |
| CID | 16220172 |
| Short Description | CFTR potentiator |
References
- F. Van Goor et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30.
- K.Y. Jih et al. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4404-9.
- P.D. Eckford et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR.... J Biol Chem. 2012 Oct 26;287(44):36639-49.
Other Categories
Get a Quote for
Loading...
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.